Shunsuke Sami
Director/Board Member at GenomIdea, Inc.
Profile
Shunsuke Sami currently works at GenomIdea, Inc., as Director from 2009.
Dr. Sami also formerly worked at AnGes USA, Inc., as Chief Executive Officer, AnGes, Inc., as Director, Vice President & Executive Officer from 2008 to 2012, IMMD, Inc., as Director-Business Development & Corporate Officer, Bristol-Myers Squibb KK, as Director & Head-Business Development, and Sumitomo Pharma Co., Ltd., as Manager-Business Development & Licensing Office.
Shunsuke Sami active positions
| Companies | Position | Start |
|---|---|---|
GenomIdea, Inc.
 GenomIdea, Inc. BiotechnologyHealth Technology Part of ISHIHARA SANGYO KAISHA LTD., GenomIdea, Inc. engages in biopharmaceutical products development and distribution. The company is based in Ibaraki, Japan. GenomIdea was acquired by ISHIHARA SANGYO KAISHA LTD. from AnGes, Inc. on January 31, 2013 for $0.0 million. | Director/Board Member | 2009-02-28 |
Former positions of Shunsuke Sami
| Companies | Position | End |
|---|---|---|
| ANGES, INC. | Director/Board Member | - |
AnGes USA, Inc.
 AnGes USA, Inc. Pharmaceuticals: MajorHealth Technology Part of AnGes, Inc., AnGes USA, Inc. develops and manufactures medicines. The company is based in Gaithersburg, MD. Ei Yamada has been the CEO of the company since 2014. | Chief Executive Officer | - |
IMMD, Inc.
 IMMD, Inc. BiotechnologyHealth Technology IMMD, Inc. provides drug discovery research for pharmaceutical companies. It identifies drug seeds by virtual screening, to select promising seeds and to optimize the seeds by minimum syntheses, based on estimated docking mode to the target. The firm also establishes a drug discovery method using software system for rational drug design based on 3-D structures of target proteins. Its business activities also include collaborative drug discovery researches, in-house drug discovery program, and drug seeds. The company was founded by Akiko Itai on March 16, 1995 and is headquartered in Tokyo, Japan. | Corporate Officer/Principal | - |
Bristol-Myers Squibb KK
 Bristol-Myers Squibb KK BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb KK develops, manufactures and markets biopharmaceutical products. The company is based in Shinjuku-ku, Japan. | Director/Board Member | - |
| SUMITOMO PHARMA CO., LTD. | Corporate Officer/Principal | - |
Experiences
Positions held
Linked companies
| Listed companies | 2 |
|---|---|
| SUMITOMO PHARMA CO., LTD. | Health Technology |
| ANGES, INC. | Health Technology |
| Private companies | 4 |
|---|---|
IMMD, Inc.
IMMD, Inc. BiotechnologyHealth Technology IMMD, Inc. provides drug discovery research for pharmaceutical companies. It identifies drug seeds by virtual screening, to select promising seeds and to optimize the seeds by minimum syntheses, based on estimated docking mode to the target. The firm also establishes a drug discovery method using software system for rational drug design based on 3-D structures of target proteins. Its business activities also include collaborative drug discovery researches, in-house drug discovery program, and drug seeds. The company was founded by Akiko Itai on March 16, 1995 and is headquartered in Tokyo, Japan. | Health Technology |
Bristol-Myers Squibb KK
Bristol-Myers Squibb KK BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb KK develops, manufactures and markets biopharmaceutical products. The company is based in Shinjuku-ku, Japan. | Health Technology |
AnGes USA, Inc.
AnGes USA, Inc. Pharmaceuticals: MajorHealth Technology Part of AnGes, Inc., AnGes USA, Inc. develops and manufactures medicines. The company is based in Gaithersburg, MD. Ei Yamada has been the CEO of the company since 2014. | Health Technology |
GenomIdea, Inc.
GenomIdea, Inc. BiotechnologyHealth Technology Part of ISHIHARA SANGYO KAISHA LTD., GenomIdea, Inc. engages in biopharmaceutical products development and distribution. The company is based in Ibaraki, Japan. GenomIdea was acquired by ISHIHARA SANGYO KAISHA LTD. from AnGes, Inc. on January 31, 2013 for $0.0 million. | Health Technology |
- Stock Market
- Insiders
- Shunsuke Sami
